title: Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.
abstract: BACKGROUND
  The potential for a drug interaction between S/GSK1349572 and tenofovir disoproxil fumarate (TDF) was evaluated in an open-label, repeat dose, 3-period, drug-drug interaction study in healthy subjects.
  
  
  METHODS
  S/GSK1349572 was administered at 50 mg once daily for 5 days (period 1) followed by a 6-day washout period. TDF 300 mg once daily was then administered for 7 days (period 2). The combination of S/GSK1349572 and TDF was then coadministered for 5 days (period 3). Pharmacokinetic parameters were determined and compared between periods.
  
  
  RESULTS
  Fifteen subjects completed all periods and follow-up. S/GSK1349572 and TDF were generally well tolerated with few adverse events reported. No clinically significant trends in post-dose laboratory abnormalities, vital signs, or electrocardiogram values were noted. Pharmacokinetic parameters of S/GSK1349572 and tenofovir during combination therapy were similar to those when given alone, demonstrating no significant drug interaction. S/GSK1349572 geometric least squares mean ratios (90% confidence interval) for AUC(0-τ), Cmax, and Cτ were 1.01 (0.908, 1.11), 0.969 (0.867, 1.08), and 0.920 (0.816, 1.04), respectively. Tenofovir geometric least squares mean ratios (90% confidence interval) for AUC(0-τ), Cmax, and Cτ were 1.12 (1.01, 1.24), 1.09 (0.974, 1.23), and 1.19 (1.04, 1.35), respectively.
  
  
  CONCLUSIONS
  S/GSK1349572 and TDF can be coadministered without dose adjustment.
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
authors.forename: Ivy
authors.initials: I
authors.lastname: Song
authors.forename: Sherene S
authors.initials: SS
authors.lastname: Min
authors.forename: Julie
authors.initials: J
authors.lastname: Borland
authors.forename: Yu
authors.initials: Y
authors.lastname: Lou
authors.forename: Shuguang
authors.initials: S
authors.lastname: Chen
authors.forename: Toru
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Wajima
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Piscitelli
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006805:Human Experimentation; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010949:Plasma / Q000737:chemistry; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine